Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C N Sternberg

Showing results (71-80 of 121) with videos related to

Pageof 13
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1992
Recombinant tumor necrosis factor for superficial bladder tumorsC N Sternberg, M G Arena, V Pansadoro, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 1, 1995
Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis?C N Sternberg, D Raghaven, Y Ohi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2014
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trialC N Sternberg, J S de Bono, K N Chi, et al.
Cancer|December 15, 1991
Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumorsA D Seidman, H I Scher, M H Heinemann, et al.
European Journal of Cancer (Oxford, England : 1990)|June 22, 2011
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trialD Cella, A S Pickard, M S Duh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2009
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancerC N Sternberg, H Dumez, H Van Poppel, et al.
ESMO Open|November 17, 2023
Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practiceP Grivas, E Grande, I D Davis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2009
Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II studyL Celio, C N Sternberg, R Labianca, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Phase I/II trial of intravesical methotrexate for superficial bladder tumorsC N Sternberg, A Yagoda, N H Bander, et al.
The Journal of Urology|March 1, 1988
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesionH I Scher, A Yagoda, H W Herr, et al.
Pageof 13

Showing results (71-80 of 121) with videos related to

Sort By:
Pageof 13
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1992
Recombinant tumor necrosis factor for superficial bladder tumorsC N Sternberg, M G Arena, V Pansadoro, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 1, 1995
Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis?C N Sternberg, D Raghaven, Y Ohi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2014
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trialC N Sternberg, J S de Bono, K N Chi, et al.
Cancer|December 15, 1991
Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumorsA D Seidman, H I Scher, M H Heinemann, et al.
European Journal of Cancer (Oxford, England : 1990)|June 22, 2011
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trialD Cella, A S Pickard, M S Duh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2009
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancerC N Sternberg, H Dumez, H Van Poppel, et al.
ESMO Open|November 17, 2023
Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practiceP Grivas, E Grande, I D Davis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2009
Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II studyL Celio, C N Sternberg, R Labianca, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Phase I/II trial of intravesical methotrexate for superficial bladder tumorsC N Sternberg, A Yagoda, N H Bander, et al.
The Journal of Urology|March 1, 1988
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesionH I Scher, A Yagoda, H W Herr, et al.
Pageof 13